Form 4: Seres Therapeutics CSO Sells Shares for Tax

Seres Therapeutics' Chief Scientific Officer, Matthew R. Henn, sold 73 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Matthew R. Henn, Chief Scientific Officer and Executive Vice President of Seres Therapeutics, Inc. (MCRB), reported transactions involving company common stock.
• On August 15, 2025, Henn acquired 141 shares and 97 shares of common stock through the vesting of restricted stock units (RSUs).
• On August 18, 2025, Henn sold 73 shares of common stock at a price of $16.65 per share.
• The sale was executed under a Rule 10b5-1 plan adopted on April 13, 2023, specifically to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Henn beneficially owns 4,548 shares of common stock directly.
• Henn also holds 844 and 976 restricted stock units, which represent contingent rights to receive common stock, with vesting schedules extending quarterly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation and tax obligations, which are generally neutral events and do not indicate a significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The sale was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to managing equity compensation rather than a discretionary sale based on market outlook.
• The sale was explicitly stated to be for tax coverage, which is a common and generally neutral reason for insider sales.

Negatives

• A small number of shares were sold by a key executive, which, while for tax purposes, still represents a reduction in direct ownership.

Future Outlook

NA

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Industry Context

NA

Stakeholder Impact

• The sale of shares by a key executive for tax purposes is a routine event and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors.

Next Steps

• Remaining restricted stock units will vest and settle in 12 equal quarterly installments after February 15, 2024, and February 15, 2025, respectively.

Key Dates

Recommendation

The reported transactions are routine insider sales for tax purposes, executed under a pre-planned Rule 10b5-1 program. Such sales are common for executives managing equity compensation and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Seres Therapeutics, MCRB, Matthew R. Henn, Insider Trading, Form 4, Restricted Stock Units, Equity Compensation, Tax Sale, Rule 10b5-1